{"created":"2023-05-15T14:38:09.064970+00:00","id":49225,"links":{},"metadata":{"_buckets":{"deposit":"0720528e-4090-4b14-9483-7ba9b427229d"},"_deposit":{"created_by":1,"id":"49225","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"49225"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00049225","sets":["1"]},"author_link":["1042007","1041999","1042011","1042004","1041997","1042005","1042001","1042009","1042002","1042010","1042008","1042000","1042012","1042014","1042003","1042013","1041996","1042006","1042016","1042015","1041998"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-06","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"7","bibliographicPageEnd":"2309","bibliographicPageStart":"2302","bibliographicVolumeNumber":"109","bibliographic_titles":[{"bibliographic_title":"Cancer Science"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Synovial sarcoma (SS) is a rare yet refractory soft-tissue sarcoma that predominantly affects young adults. We show in a mouse model that radioimmunotherapy (RIT) with an α-particle emitting anti-Frizzled homolog 10 (FZD10) antibody, synthesized using the α-emitter radionuclide astatine-211 (211At-OTSA101), suppresses the growth of SS xenografts more efficiently than the corresponding β-particle emitting anti-FZD10 antibody conjugated with the β-emitter yettrium-90 (90Y-OTSA101). In biodistribution analysis, 211At was increased in the SS xenografts but decreased in other tissues up to 1 day after injection as time proceeded, albeit with a relatively higher uptake in the stomach. Single 211At-OTSA101 doses of 25 and 50 μCi significantly suppressed SS tumor growth in vivo, whereas a 50 μCi dose of 90Y-OTSA101 was needed to achieve this. Importantly, 50 μCi of 211At-OTSA101 suppressed tumor growth immediately after injection, whereas this effect required several days in the case of 90Y-OTSA101. Both radiolabeled antibodies at the 50 μCi dosage level significantly prolonged survival. Histopathologically, severe cellular damage accompanied by massive cell death was evident in the SS xenografts at even 1 day after the 211At-OTSA101 injection but these effects were relatively milder with 90Y-OTSA101 at the same timepoint, even though the absorbed doses were comparable (3.3 and 3.0 Gy, respectively). We conclude that α-particle RIT with 211At-OTSA101 is a potential new therapeutic option for SS. ","subitem_description_type":"Abstract"}]},"item_8_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Wiley"}]},"item_8_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1111/cas.13636","subitem_relation_type_select":"DOI"}}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1347-9032","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Li, Huizi"}],"nameIdentifiers":[{"nameIdentifier":"1041996","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sugyo, Aya"}],"nameIdentifiers":[{"nameIdentifier":"1041997","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsuji, Atsushi"}],"nameIdentifiers":[{"nameIdentifier":"1041998","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Morokoshi, Yukie"}],"nameIdentifiers":[{"nameIdentifier":"1041999","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Minegishi, Katsuyuki"}],"nameIdentifiers":[{"nameIdentifier":"1042000","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nagatsu, Kotaro"}],"nameIdentifiers":[{"nameIdentifier":"1042001","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kanda, Hiroaki"}],"nameIdentifiers":[{"nameIdentifier":"1042002","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Harada, Yosuke"}],"nameIdentifiers":[{"nameIdentifier":"1042003","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nagayama, Satoshi"}],"nameIdentifiers":[{"nameIdentifier":"1042004","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Katagiri, Toyomasa"}],"nameIdentifiers":[{"nameIdentifier":"1042005","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nakamura, Yusuke"}],"nameIdentifiers":[{"nameIdentifier":"1042006","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Higashi, Tatsuya"}],"nameIdentifiers":[{"nameIdentifier":"1042007","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hasegawa, Sumitaka"}],"nameIdentifiers":[{"nameIdentifier":"1042008","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Li, Huizi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1042009","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Aya, Sugyo","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1042010","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Atsushi, Tsuji","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1042011","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yukie, Morokoshi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1042012","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Katsuyuki, Minegishi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1042013","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kotaro, Nagatsu","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1042014","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tatsuya, Higashi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1042015","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sumitaka, Hasegawa","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1042016","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"α-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"α-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10"}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-07-09"},"publish_date":"2018-07-09","publish_status":"0","recid":"49225","relation_version_is_last":true,"title":["α-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T17:22:11.773513+00:00"}